Capstone Therapeutics (CAPS) Misses Q1 EPS by 2c

Capstone Therapeutics (NASDAQ: CAPS) reported Q1 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $10.5 million.

For earnings history and earnings-related data on Capstone Therapeutics (CAPS) click here.

You May Also Be Interested In

• FDA accepts Teva's drug application for Tourette syndrome therapy in children
• ZIM Integrated Shipping Services Ltd. (ZIM) Tops Q2 EPS by 82c
• Cosmos Health posts 29% revenue gain in Q2 but widens net loss